▶ Full Post Text
I’ve been looking at Zoetis after the recent selloff, and I think it is an interesting value setup.
**The simple question:**
Is Zoetis facing a structural impairment in companion animal demand and pricing power, or is the market overreacting to a cyclical pet-care slowdown and a messy reset in expectations?
**This used to be an easy pass for me.**
At 30x+ earnings, Zoetis may have been a great business, but the valuation did not make much sense. At roughly 11x forward earnings, the question changes.
Zoetis is a global animal health company across medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health. If you own a dog, you may know them through Simparica Trio.
**The bear case is real:**
\- U.S. companion animal revenue declined 11% YoY
\- vet clinic traffic is softer
\- pet owners are more price-sensitive
\- Credelio Quattro is a credible competitor to Simparica Trio
\- dermatology is under pressure
\- Librela remains an overhang
\- management cut 2026 guidance
So I do not think the market is reacting to nothing. *The question is whether this is a structural break or a reset in expectations.*
**The reason I am interested is that the quality profile still does not look broken:**
**- Gross margin around 70%**
**- Operating margin in the mid-30s**
**- ROE around 40%**
**- ROIC around 18%-20%**
**- ROCE around 20%+**
**- Forward payout ratio around 30%**
**- BBB+ credit rating**
**- Net debt/EBITDA around 1.65x**
**- Interest coverage around 15x**
Those are not the numbers of a low-quality business or a financially stressed one.
**My current view is that the Zoetis flywheel still looks largely intact:** high margins, strong free cash flow, trusted veterinary distribution, R&D reinvestment, new products, pricing power, and then more cash to reinvest again.
The valuation is what makes it interesting to me.
**Forward EPS expectations are roughly:**
**2026: $6.85-$7.00**
**2027: \~$7.40**
**2028: \~$7.96**
If Zoetis can stabilize the business and eventually trade closer to 20x earnings, you can get to a materially higher stock price without assuming a return to the old 30x+ multiple.
**That is the core thesis: Zoetis does not need to become expensive again. It just needs to prove the flywheel is not broken.**
**What would make me wrong:**
If the pet-care slowdown is structural, if Zoetis loses share in key franchises, if pricing power fades, if Librela or other product issues damage trust with vets, or if the R&D pipeline fails to offset pressure in existing products, then the old margin and multiple structure probably no longer applies.
**I think this can go very wrong or very right, which is usually where I start paying attention.**
**Curious how others are thinking about ZTS. Is this a broken compounder, or is the market pricing in too much permanent impairment?**
**Disclosure: I now own shares! Not investment advice.**